Cynapsus Therapeutics Inc. (Cynapsus Therapeutics) is a Canada-based specialty pharmaceutical company. The Company is developing sublingual (oral) thin film strip for the rescue of off motor symptoms of Parkinson�s disease. The Company�s drug candidate, APL-130277, is a fast-acting reformulation of apomorphine, which is approved in the United States, Europe, Japan and other countries, to rescue patients from off episodes of Parkinson�s disease. APL-130277 is a bilayer film designed to facilitate the delivery of the drug through the oral mucosal route under the tongue. Cynapsus Therapeutics is focused on the clinical development and maximizing the commercialization potential of APL-130277, primarily through a semi-virtual outsourcing business model integrating formulation developers, Active Pharmaceutical Ingredient (API) suppliers, regulatory and intellectual property experts, neuroscientists and central nervous system researchers.